Literature DB >> 16546316

Frozen section for the management of intraoperatively detected palpable tumor lesions during nerve-sparing scheduled radical prostatectomy.

Christian Eichelberg1, Andreas Erbersdobler, Alexander Haese, Thorsten Schlomm, Felix K H Chun, Eike Currlin, Jochen Walz, Thomas Steuber, Markus Graefen, Hartwig Huland.   

Abstract

OBJECTIVES: The intraoperative finding of palpable tumor lesions has been described as a contraindication for nerve-sparing (NS) radical prostatectomy (RP). However, its evaluation is subjective. Especially in patients with a strong demand to regain postoperative erectile function, a surgeon might be reluctant to sacrifice neurovascular bundles (NVBs) based on this information. We investigated the use of frozen section (FS) analysis to monitor the safety and efficiency of NS during RP in patients with intraoperatively identified subcapsular tumor lesions.
METHODS: In 83 of 608 patients, who underwent NS-RP, intraoperative FS was performed because of a lesion palpable close to the capsule. A wedge of 4cm in diameter including the lesion was cut off and stained differently for capsule and intraprostatic margin. In case of presence of carcinoma adherent to the capsule, the NVB was resected; otherwise, the NVB remained in situ.
RESULTS: Patients with palpable tumor lesions had pT3 tumors in 36% and 61% had Gleason 4 pattern, compared to 18% and 42% for the control group. Carcinoma was found in 93% of the FS specimens. In 42% of the FS samples, tumor had contact with the capsule and 14% of secondary resected NVB specimens demonstrated a carcinoma invasion. In 52% NVBs could be preserved despite an ipsilateral nodule without negatively affecting the margin status. However, the false-negative rate of the FSs was 6%. Conversely, FSs set the intraoperative decision to remove the NVB in 42% of FS patients, resulting in an additional 36% of negative margins.
CONCLUSIONS: In patients with intraoperatively detected tumor lesions during a NS planned RP, FS objectively supports the decision of secondary NVB resection as well as preservation.

Entities:  

Mesh:

Year:  2006        PMID: 16546316     DOI: 10.1016/j.eururo.2006.02.035

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  10 in total

1.  Macrocryosectioning and complete sampling of the prostate in a potential multiorgan donor candidate.

Authors:  Roberta Mazzucchelli; Marina Scarpelli; Antonio Lopez-Beltran; Liang Cheng; Rodolfo Montironi
Journal:  J Clin Pathol       Date:  2007-08       Impact factor: 3.411

Review 2.  Value of frozen section biopsies during radical prostatectomy: significance of the histological results.

Authors:  Miguel Ramírez-Backhaus; Robert Rabenalt; Sunjay Jain; Minh Do; Evangelos Liatsikos; Roman Ganzer; Lars-Christian Horn; Martin Burchardt; Fernando Jiménez-Cruz; Jens-Uwe Stolzenburg
Journal:  World J Urol       Date:  2008-12-10       Impact factor: 4.226

Review 3.  Function-preserving surgery for urologic cancer.

Authors:  Kenichi Tobisu
Journal:  Int J Clin Oncol       Date:  2006-10       Impact factor: 3.402

4.  Prostate Cancer Detection Using Composite Impedance Metric.

Authors:  Shadab Khan; Aditya Mahara; Elias S Hyams; Alan R Schned; Ryan J Halter
Journal:  IEEE Trans Med Imaging       Date:  2016-06-09       Impact factor: 10.048

5.  Clinical impact of intraoperative frozen sections during nerve-sparing radical prostatectomy.

Authors:  Elmar Heinrich; Georg Schön; Frank Schiefelbein; Maurice Stephan Michel; Lutz Trojan
Journal:  World J Urol       Date:  2010-04-01       Impact factor: 4.226

6.  Label-free high-resolution imaging of prostate glands and cavernous nerves using coherent anti-Stokes Raman scattering microscopy.

Authors:  Liang Gao; Haijun Zhou; Michael J Thrall; Fuhai Li; Yaliang Yang; Zhiyong Wang; Pengfei Luo; Kelvin K Wong; Ganesh S Palapattu; Stephen T C Wong
Journal:  Biomed Opt Express       Date:  2011-03-18       Impact factor: 3.732

7.  Multiparametric magnetic resonance imaging and frozen-section analysis efficiently predict upgrading, upstaging, and extraprostatic extension in patients undergoing nerve-sparing robotic-assisted radical prostatectomy.

Authors:  Roberto Bianchi; Gabriele Cozzi; Giuseppe Petralia; Sarah Alessi; Giuseppe Renne; Danilo Bottero; Antonio Brescia; Antonio Cioffi; Giovanni Cordima; Matteo Ferro; Deliu Victor Matei; Federica Mazzoleni; Gennaro Musi; Francesco Alessandro Mistretta; Alessandro Serino; Valeria Maria Lucia Tringali; Ioan Coman; Ottavio De Cobelli
Journal:  Medicine (Baltimore)       Date:  2016-10       Impact factor: 1.889

8.  NeuroSAFE robot-assisted laparoscopic prostatectomy versus standard robot-assisted laparoscopic prostatectomy for men with localised prostate cancer (NeuroSAFE PROOF): protocol for a randomised controlled feasibility study.

Authors:  Eoin Dinneen; Aiman Haider; Clare Allen; Alex Freeman; Tim Briggs; Senthil Nathan; Chris Brew-Graves; Jack Grierson; Norman R Williams; Raj Persad; Neil Oakley; Jim M Adshead; Hartwig Huland; Alexander Haese; Greg Shaw
Journal:  BMJ Open       Date:  2019-06-11       Impact factor: 2.692

9.  NeuroSAFE PROOF: study protocol for a single-blinded, IDEAL stage 3, multi-centre, randomised controlled trial of NeuroSAFE robotic-assisted radical prostatectomy versus standard robotic-assisted radical prostatectomy in men with localized prostate cancer.

Authors:  Eoin Dinneen; Jack Grierson; Ricardo Almeida-Magana; Rosie Clow; Aiman Haider; Clare Allen; Daniel Heffernan-Ho; Alex Freeman; Tim Briggs; Senthil Nathan; Susan Mallett; Chris Brew-Graves; Nicola Muirhead; Norman R Williams; Elena Pizzo; Raj Persad; Jon Aning; Lyndsey Johnson; Jon Oxley; Neil Oakley; Susan Morgan; Fawzia Tahir; Imran Ahmad; Lorenzo Dutto; Jonathan M Salmond; Anand Kelkar; John Kelly; Greg Shaw
Journal:  Trials       Date:  2022-07-22       Impact factor: 2.728

10.  The value of transperineal apical prostate biopsy in predicting urethral/apical margin status after radical prostatectomy.

Authors:  Jindong Dai; Xingming Zhang; Jinge Zhao; Guangxi Sun; Junru Chen; Jiandong Liu; Ronggui Tao; Hao Zeng; Pengfei Shen
Journal:  Medicine (Baltimore)       Date:  2019-10       Impact factor: 1.817

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.